Conclusion
To summarize, the use of nirmatrelvir-ritonavir within 10 days of symptom onset or a positive RT-PCR result is linked to a reduced duration of RT-PCR conversion in high-risk patients infected with SARS-CoV-2. This expands the potential use of nirmatrelvir-ritonavir beyond its labeled indications.